Bavarian Biotech Report 2011/2012 (7MB) - Bio M

ALGORA Gesellschaft für Medizinstatistikund Vertriebssysteme mbHCROKeywords: Oncology, Monitoring, Clinical Research, Infectious DiseasesAlgora is a niche CRO successfully operating on clinical trials in Germany.Services include phase II-IV trials as well as large observational studies andrange from protocol development to final study reports. Algora managescomplete study projects or delivers individual services, such as clinicalmonitoring, data management or statistical analysis. Experienced in oncologysince the first days of the company in 1989, Algora always had a focus oninnovative therapies, leading to close relationships to university hospitalsand medical societies. Since 1995 another focus developed in large pediatricstudies. Customers are pharmaceutical and medical device companies,independent research groups, and other CROs.Contact:Dr. Karl FehnleMünchner Str. 11D-85540 HaarPhone: +49 (0) 89 613727-0Fax: +49 (0) 89 613727-20E-Mail: cro@algora.deInternet: www.algora.deAMGEN GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Clinical Research, Oncology, Bone / Joint Diseases, NephrologyAmgen discovers, develops, manufactures and delivers innovative humantherapeutics. A biotechnology pioneer since 1980, Amgen was one of thefirst companies to realize the new science’s promise by bringing safe andeffective medicines from lab, to manufacturing plant, to patient. Amgentherapeutics have changed the practice of medicine, helping millions of peoplearound the world in the fight against cancer, kidney disease, rheumatoidarthritis, and other serious illnesses. With a deep and broad pipeline ofpotential new medicines, Amgen remains committed to advancing scienceto dramatically improve people‘s lives. To learn more about our pioneeringscience and our vital medicines, please visit www.amgen.com orwww.amgen.deContact:Dr. Karl-Heinz GrajerHanauerstr. 1D-80992 MünchenPhone: +49 (0) 89 149096-1600Fax: +49 (0) 89 149096-2600E-Mail: karl-heinz.grajer@amgen.comInternet: www.amgen.deAMGEN Research GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Metabolic Diseases, Oncology, Neurology, Inflammation, Hematology,Small Molecules, Drug DevelopmentAMGEN, (Applied Molecular Genetics Inc.) was founded in 1980 as one ofthe pioneers of industrial biotechnology. The company develops, producesand sells biopharmaceutical products that are produced through recombinantDNA technologies as well as small molecule therapeutics. AMGENResearch GmbH was founded in Regensburg in 2000. Basic research is conductedwith the aim of identifying new pharmaceutical lead structures forthe development of innovative drugs. Low molecular weight compoundsare identified by high throughput screening (HTS) procedures. Over 10million compounds are analyzed every year.Contact:Mirko StemmlerJosef-Engert-Str. 11D-93053 RegensburgPhone: +49 (0) 941 465-20000Fax: +49 (0) 941 465-20100E-Mail: Mirko.Stemmler@amgen.comInternet: www.amgen.de35